CHO Pharma, Inc. (TPEX: 6586)
Taiwan
· Delayed Price · Currency is TWD 60.50
-1.20 (-1.94%)
Sep 10, 2024, 3:00 PM CST
CHO Pharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 117.77 | 203.79 | 505.66 | 777.98 | 986.39 | 1,264 | Upgrade
|
| Short-Term Investments | 2,372 | 2,399 | 538.9 | 538.9 | 538.9 | 538.9 | Upgrade
|
| Cash & Short-Term Investments | 2,490 | 2,603 | 1,045 | 1,317 | 1,525 | 1,803 | Upgrade
|
| Cash Growth | 178.99% | 149.17% | -20.68% | -13.66% | -15.42% | -13.30% | Upgrade
|
| Accounts Receivable | 0.42 | - | - | 0.06 | - | - | Upgrade
|
| Other Receivables | 3.36 | 2.09 | 0.09 | 0.08 | 0.09 | 0.09 | Upgrade
|
| Receivables | 3.78 | 2.09 | 0.09 | 0.14 | 0.09 | 0.09 | Upgrade
|
| Other Current Assets | 42.61 | 38.23 | 34.8 | 23.62 | 21.29 | 17.59 | Upgrade
|
| Total Current Assets | 2,536 | 2,643 | 1,079 | 1,341 | 1,547 | 1,821 | Upgrade
|
| Property, Plant & Equipment | 44.21 | 8.2 | 19.74 | 37.23 | 62.51 | 56.84 | Upgrade
|
| Other Intangible Assets | 428.3 | 431.8 | 497.23 | 509.93 | 528.63 | 533.53 | Upgrade
|
| Other Long-Term Assets | 2.66 | 3.02 | 5.84 | 5.91 | 5.15 | 13.79 | Upgrade
|
| Total Assets | 3,011 | 3,086 | 1,602 | 1,894 | 2,143 | 2,425 | Upgrade
|
| Accrued Expenses | 87.53 | 99.43 | 150.85 | 113.04 | 130.38 | 115.89 | Upgrade
|
| Current Portion of Leases | 14.17 | - | 11.7 | 13.87 | 12.59 | 11.45 | Upgrade
|
| Other Current Liabilities | 6.55 | 6.6 | 6.35 | 6.31 | 6.23 | 5.4 | Upgrade
|
| Total Current Liabilities | 108.26 | 106.03 | 168.9 | 133.22 | 149.2 | 132.74 | Upgrade
|
| Long-Term Leases | 21.78 | - | - | 11.7 | 25.67 | 29.03 | Upgrade
|
| Other Long-Term Liabilities | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 | - | Upgrade
|
| Total Liabilities | 134.83 | 110.83 | 173.7 | 149.71 | 179.67 | 161.78 | Upgrade
|
| Common Stock | 2,140 | 2,140 | 1,840 | 1,839 | 1,838 | 1,836 | Upgrade
|
| Additional Paid-In Capital | 1,145 | 1,688 | 135.73 | 410.58 | 782.73 | 1,094 | Upgrade
|
| Retained Earnings | -406.06 | -850.41 | -544.32 | -502.76 | -655.21 | -664.94 | Upgrade
|
| Comprensive Income & Other | -2.71 | -2.75 | -2.79 | -3.25 | -2.53 | -1.6 | Upgrade
|
| Shareholders' Equity | 2,876 | 2,975 | 1,429 | 1,744 | 1,963 | 2,263 | Upgrade
|
| Total Liabilities & Equity | 3,011 | 3,086 | 1,602 | 1,894 | 2,143 | 2,425 | Upgrade
|
| Total Debt | 35.95 | - | 11.7 | 25.56 | 38.26 | 40.49 | Upgrade
|
| Net Cash (Debt) | 2,454 | 2,603 | 1,033 | 1,291 | 1,487 | 1,763 | Upgrade
|
| Net Cash Growth | 176.78% | 151.99% | -20.02% | -13.16% | -15.65% | -15.25% | Upgrade
|
| Net Cash Per Share | 11.89 | 13.60 | 5.61 | 7.02 | 8.10 | 9.63 | Upgrade
|
| Filing Date Shares Outstanding | 214.01 | 214.01 | 183.99 | 183.94 | 183.68 | 183.57 | Upgrade
|
| Total Common Shares Outstanding | 214.01 | 214.01 | 183.99 | 183.94 | 183.68 | 183.57 | Upgrade
|
| Working Capital | 2,428 | 2,537 | 910.56 | 1,207 | 1,397 | 1,688 | Upgrade
|
| Book Value Per Share | 13.44 | 13.90 | 7.76 | 9.48 | 10.69 | 12.33 | Upgrade
|
| Tangible Book Value | 2,448 | 2,543 | 931.34 | 1,234 | 1,435 | 1,730 | Upgrade
|
| Tangible Book Value Per Share | 11.44 | 11.88 | 5.06 | 6.71 | 7.81 | 9.42 | Upgrade
|
| Machinery | 110.2 | 107.99 | 104.61 | 96.59 | 95.3 | 87.51 | Upgrade
|
| Leasehold Improvements | 20.69 | 20.38 | 19.82 | 18.6 | 18.66 | 2.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.